Ensysce Biosciences (ENSCW) Amortization of Deferred Charges (2024 - 2025)
Ensysce Biosciences (ENSCW) reported Amortization of Deferred Charges of $300000.0 for Q1 2025, down 74.39% year-over-year from $1.2 million in Q1 2024, and up 1065.73% quarter-over-quarter from $25735.0 in Q2 2024.
Ensysce Biosciences (ENSCW) Amortization of Deferred Charges (2024 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 2 years of Amortization of Deferred Charges data on file, last reported at $300000.0 in Q1 2025.
- Amortization of Deferred Charges for Q1 2025 came in at $300000.0, down 74.39% year-over-year; the trailing twelve-month figure through Dec 2025 was $300000.0 (down 74.94% YoY), and the FY2025 annual result was $300000.0, down 74.94% from the prior year.
- Amortization of Deferred Charges improved to $300000.0 in Q1 2025 per ENSCW's latest filing, from $25735.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $1.2 million in Q1 2024 and troughed at $25735.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ensysce Biosciences | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Jun 30, 2024 | 25,735.00 |
| Jun 30, 2024 | 25,735.00 |
| Mar 31, 2024 | 1.17 Mn |
| Mar 31, 2024 | 1.17 Mn |